EZH2 and neoplasm: Of note, a recent study by Takata et al. demonstrated that in patients with diffuse large B-cell lymphoma (DLBCL), PRAME-deleted tumours showed cytotoxic T-cell immune escape and were associated with cold tumour microenvironments with the enhancer of zeste homolog 2–activating (EZH2-activating) mutations suppressing PRAME expression.